Biomarker panels associated with progression of renal disease in type 1 diabetes

Show full item record

Permalink

http://hdl.handle.net/10138/305363

Citation

Finndiane Study Grp , SDRN Type 1 Bioresource Collabora , Colombo , M , Valo , E , Sandholm , N , Groop , P-H , Forsblom , C & Colhoun , H M 2019 , ' Biomarker panels associated with progression of renal disease in type 1 diabetes ' , Diabetologia , vol. 62 , no. 9 , pp. 1616-1627 . https://doi.org/10.1007/s00125-019-4915-0

Title: Biomarker panels associated with progression of renal disease in type 1 diabetes
Author: Colombo, Marco; Valo, Erkka; McGurnaghan, Stuart J.; Sandholm, Niina; Blackbourn, Luke A. K.; Dalton, R. Neil; Dunger, David; Groop, Per-Henrik; McKeigue, Paul M.; Forsblom, Carol; Colhoun, Helen M.
Contributor: University of Helsinki, HUS Abdominal Center
University of Helsinki, HUS Abdominal Center
University of Helsinki, HUS Abdominal Center
University of Helsinki, Research Programs Unit
Date: 2019-09
Number of pages: 12
Belongs to series: Diabetologia
ISSN: 0012-186X
URI: http://hdl.handle.net/10138/305363
Abstract: Aims/hypothesis We aimed to identify a sparse panel of biomarkers for improving the prediction of renal disease progression in type 1 diabetes. Methods We considered 859 individuals recruited from the Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) and 315 individuals from the Finnish Diabetic Nephropathy (FinnDiane) study. All had an entry eGFR between 30 and 75 ml min(-1)[1.73 m](-2), with those from FinnDiane being oversampled for albuminuria. A total of 297 circulating biomarkers (30 proteins, 121 metabolites, 146 tryptic peptides) were measured in non-fasting serum samples using the Luminex platform and LC electrospray tandem MS (LC-MS/MS). We investigated associations with final eGFR adjusted for baseline eGFR and with rapid progression (a loss of more than 3 ml min(-1)[1.73 m](-2) year(-1)) using linear and logistic regression models. Panels of biomarkers were identified using a penalised Bayesian approach, and their performance was evaluated through 10-fold cross-validation and compared with using clinical record data alone. Results For final eGFR, 16 proteins and 30 metabolites or tryptic peptides showed significant association in SDRNT1BIO, and nine proteins and five metabolites or tryptic peptides in FinnDiane, beyond age, sex, diabetes duration, study day eGFR and length of follow-up (all at p <10(-4)). The strongest associations were with CD27 antigen (CD27), kidney injury molecule 1 (KIM-1) and alpha 1-microglobulin. Including the Luminex biomarkers on top of baseline covariates increased the r(2) for prediction of final eGFR from 0.47 to 0.58 in SDRNT1BIO and from 0.33 to 0.48 in FinnDiane. At least 75% of the increment in r(2) was attributable to CD27 and KIM-1. However, using the weighted average of historical eGFR gave similar performance to biomarkers. The LC-MS/MS platform performed less well. Conclusions/interpretation Among a large set of associated biomarkers, a sparse panel of just CD27 and KIM-1 contains most of the predictive information for eGFR progression. The increment in prediction beyond clinical data was modest but potentially useful for oversampling individuals with rapid disease progression into clinical trials, especially where there is little information on prior eGFR trajectories.
Subject: Clinical science
Epidemiology
Metabolomics
Nephropathy
Proteomics
KIDNEY INJURY MOLECULE-1
SERUM CYSTATIN-C
NEPHROPATHY
DECLINE
MODELS
ESRD
3111 Biomedicine
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Colombo2019_Art ... rPanelsAssociatedWithP.pdf 706.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record